121 related articles for article (PubMed ID: 23098381)
1. Validation and comparison of diagnostic accuracy of four screening tools for mental disorders in people seeking treatment for substance use disorders.
Rush B; Castel S; Brands B; Toneatto T; Veldhuizen S
J Subst Abuse Treat; 2013 Apr; 44(4):375-83. PubMed ID: 23098381
[TBL] [Abstract][Full Text] [Related]
2. A validation study of the Four-Dimensional Symptom Questionnaire (4DSQ) in insurance medicine.
Langerak W; Langeland W; van Balkom A; Draisma S; Terluin B; Draijer N
Work; 2012; 43(3):369-80. PubMed ID: 22927600
[TBL] [Abstract][Full Text] [Related]
3. [Screening of psychopathology with juvenile deviants].
Gutschner D; Völkl-Kernstock S; Perret A; Doreleijers T; Vermeiren R; Fegert JM; Schmeck K
Neuropsychiatr; 2011; 25(1):26-35. PubMed ID: 21486541
[TBL] [Abstract][Full Text] [Related]
4. Screening for serious mental illness in populations with co-occurring substance use disorders: Performance of the K6 scale.
Swartz JA; Lurigio AJ
J Subst Abuse Treat; 2006 Oct; 31(3):287-96. PubMed ID: 16996391
[TBL] [Abstract][Full Text] [Related]
5. "Do you think you have mental health problems?": advantages and disadvantages of a single screening question for mental disorder in substance use disorder treatment.
Veldhuizen S; Rush B; Urbanoski K
J Stud Alcohol Drugs; 2014 Nov; 75(6):1039-46. PubMed ID: 25343663
[TBL] [Abstract][Full Text] [Related]
6. Brief case finding tools for anxiety disorders: validation of GAD-7 and GAD-2 in addictions treatment.
Delgadillo J; Payne S; Gilbody S; Godfrey C; Gore S; Jessop D; Dale V
Drug Alcohol Depend; 2012 Sep; 125(1-2):37-42. PubMed ID: 22480667
[TBL] [Abstract][Full Text] [Related]
7. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment.
Baker KD; Lubman DI; Cosgrave EM; Killackey EJ; Yuen HP; Hides L; Baksheev GN; Buckby JA; Yung AR
Aust N Z J Psychiatry; 2007 Nov; 41(11):896-902. PubMed ID: 17924242
[TBL] [Abstract][Full Text] [Related]
8. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
9. Screening for depression in epilepsy clinics. A comparison of conventional and visual-analog methods.
Rampling J; Mitchell AJ; Von Oertzen T; Docker J; Jackson J; Cock H; Agrawal N
Epilepsia; 2012 Oct; 53(10):1713-21. PubMed ID: 22765759
[TBL] [Abstract][Full Text] [Related]
10. Factor structure and diagnostic efficiency of the BDI-II in treatment-seeking substance users.
Seignourel PJ; Green C; Schmitz JM
Drug Alcohol Depend; 2008 Mar; 93(3):271-8. PubMed ID: 18093749
[TBL] [Abstract][Full Text] [Related]
11. Screening for mental disorders in leprosy patients: comparing the internal consistency and screening properties of HADS and GHQ-12.
Senturk V; Stewart R; Sagduyu A
Lepr Rev; 2007 Sep; 78(3):231-42. PubMed ID: 18035774
[TBL] [Abstract][Full Text] [Related]
12. Screening for mental disorders in cardiology outpatients.
Birket-Smith M; Rasmussen A
Nord J Psychiatry; 2008; 62(2):147-50. PubMed ID: 18569779
[TBL] [Abstract][Full Text] [Related]
13. Clinician-rated versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance misuse.
Goldberg JF; Garakani A; Ackerman SH
J Clin Psychiatry; 2012 Dec; 73(12):1525-30. PubMed ID: 23290325
[TBL] [Abstract][Full Text] [Related]
14. Global Appraisal of Individual Needs Short Screener (GSS): psychometric properties and performance as a screening measure in adolescents.
McDonell MG; Comtois KA; Voss WD; Morgan AH; Ries RK
Am J Drug Alcohol Abuse; 2009; 35(3):157-60. PubMed ID: 19462299
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of DSM-IV disorders and attendant help-seeking in 2 American Indian reservation populations.
Beals J; Manson SM; Whitesell NR; Spicer P; Novins DK; Mitchell CM
Arch Gen Psychiatry; 2005 Jan; 62(1):99-108. PubMed ID: 15630077
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Alcohol Use Disorders Identification Test and the Drug Use Disorders Identification Test in a Swedish sample of suspected offenders with signs of mental health problems: results from the Mental Disorder, Substance Abuse and Crime study.
Durbeej N; Berman AH; Gumpert CH; Palmstierna T; Kristiansson M; Alm C
J Subst Abuse Treat; 2010 Dec; 39(4):364-77. PubMed ID: 20822878
[TBL] [Abstract][Full Text] [Related]
17. Screening for psychiatric disorders in outpatients with DSM-IV substance use disorders.
Zimmerman M; Sheeran T; Chelminski I; Young D
J Subst Abuse Treat; 2004 Apr; 26(3):181-8. PubMed ID: 15063911
[TBL] [Abstract][Full Text] [Related]
18. Ultra-rapid screening for substance-use disorders: the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite).
Ali R; Meena S; Eastwood B; Richards I; Marsden J
Drug Alcohol Depend; 2013 Sep; 132(1-2):352-61. PubMed ID: 23561823
[TBL] [Abstract][Full Text] [Related]
19. Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness.
Rosenberg SD; Drake RE; Wolford GL; Mueser KT; Oxman TE; Vidaver RM; Carrieri KL; Luckoor R
Am J Psychiatry; 1998 Feb; 155(2):232-8. PubMed ID: 9464203
[TBL] [Abstract][Full Text] [Related]
20. Psychiatric morbidity and its screening in Turkish women with breast cancer: a comparison between the HADS and SCID tests.
Ozalp E; Soygür H; Cankurtaran E; Turhan L; Akbiyik D; Geyik P
Psychooncology; 2008 Jul; 17(7):668-75. PubMed ID: 17992701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
